

Narrowing of the main artery by the build-up of calcium in patients with type 2 diabetes

| | | |
|--|--|--|
| Submission date 18/04/2020 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| | | <input type="checkbox"/> Protocol |
| Registration date 20/04/2020 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan |
| | | <input type="checkbox"/> Results |
| Last Edited 20/04/2020 | Condition category Nutritional, Metabolic, Endocrine | <input type="checkbox"/> Individual participant data |
| | | <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Background and study aims

Type 2 diabetes is a common condition that causes the level of sugar (glucose) in the blood to become too high. It's caused by problems with a chemical in the body (hormone) called insulin. It's often linked to being overweight or inactive, or having a family history of type 2 diabetes. Type 2 diabetes accelerates atherosclerosis and increases cardiovascular disease (CVD) morbidity including coronary artery disease (CAD), cerebral infarction (CI), and peripheral artery disease (PAD). The clinical assessment of cardiovascular risk in individual patients with type 2 diabetes is required for proper management. However, little is known about the significance of each clinical indicator in estimating disease progression.

The aorta is the main artery of the body, supplying oxygenated blood to the circulatory system. Abdominal aortic calcification occurs when calcium crystals are deposited in the abdominal aorta. This can cause the aorta to narrow and restrict blood flow. Abdominal aortic calcification (AAC) is a known marker of systemic atherosclerosis burden. The risk of AAC is reportedly lower among Hispanic and African Americans, but not among Chinese-Americans, compared with the risk in Caucasians. These ethnic differences in the significance of AAC cannot be explained by differences in classical CVD risk factors. The prevalence of coronary calcification also reportedly differs between Caucasians and Chinese, despite similar prevalences of AAC in these two ethnic groups. Few studies have investigated the clinical significance of AAC in patients with type 2 diabetes.

In this study, the researchers investigated the association between AAC and CVD and explored factors related to AAC progression in Japanese patients with type 2 diabetes.

Who can participate?

Adults aged 20 or over with type 2 diabetes.

What does the study involve?

Participants who had undergone a standing lateral abdominal radiography examination between 2 months before and 2 months after admission were eligible for inclusion in this study. AAC was evaluated using two methods, AAC score and AAC length, based on the results of standing lateral abdominal radiography examinations.

What are the possible benefits and risks of participating?

There are no direct benefits involved with participating. Risks relate to radiation, but they are relatively low.

Where is the study run from?

Yokohama City University Hospital (Japan)

When is the study starting and how long is it expected to run for?

January 2016 to March 2018

Who is funding the study?

The Japan Society for the Promotion of Science

Who is the main contact?

Jun Shirakawa, MD, PhD

jshira-ty@umin.ac.jp

Contact information

Type(s)

Scientific

Contact name

Dr Jun Shirakawa

ORCID ID

<https://orcid.org/0000-0002-0822-8750>

Contact details

Yokohama City University

Fuku-ura 3-9

Kanazawa-ku

Yokohama

Japan

236-0004

+81 (0)457872639

jshira-ty@umin.ac.jp

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

B180900053

Study information

Scientific Title

Association of abdominal aortic calcification with coronary artery disease or other factors in type 2 diabetes

Acronym

AAC in T2D

Study objectives

Abdominal aortic calcification is associated with cardiovascular disease morbidity in patients with type 2 diabetes

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 12/10/2018, Clinical Ethics Committee of Yokohama City University (Fuku-ura 3-9, Kanazawa-ku, Yokohama 236-0004, Japan; +81-45-370-7627; rinri@yokohama-cu.ac.jp), ref: B180900053

Study design

Retrospective cross-sectional study

Primary study design

Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Type 2 diabetes

Interventions

The subjects included Japanese type 2 diabetes patients who had been hospitalized at Yokohama City University Hospital between January 1, 2016, and March 31, 2018. The lateral view of an abdominal X-ray image obtained while each subject was in a standing position will be examined, and the AAC score and AAC length, corresponding to the area of calcific deposits in the anterior and posterior aortic wall for the L1-4 and L1-5 regions, respectively, measured. The associations between the AAC scores and lengths and the presence of coronary artery disease, cerebral infarction, and peripheral artery disease are then assessed. The correlation between the AAC grades and other clinical factors are also evaluated.

Intervention Type

Other

Primary outcome(s)

Measured using patient records at the time of data collection:

1. AAC score
2. AAC length
3. Presence of cardiovascular diseases, such as CAD, CI, and PAD

Key secondary outcome(s)

Factors associated with AAC score or AAC length measured using patient records at the time of data collection

Completion date

02/12/2018

Eligibility

Key inclusion criteria

1. Japanese type 2 diabetes patients who had been hospitalized at Yokohama City University Hospital between January 1, 2016, and March 31, 2018.
2. Aged 20 years or older
2. Undergone a standing lateral abdominal radiography examination between 2 months before and 2 months after admission

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

285

Key exclusion criteria

1. Severe hepatic disorders
2. Psychiatric disorders
3. Cancers
4. Severe ketosis, diabetic coma or precoma
5. Severe infections
6. Severe traumatic injuries
7. Pancreatic exocrine diseases

- 8. Hepatic cirrhosis
- 9. Endocrine diseases
- 10. Postoperative patients

Date of first enrolment

01/01/2016

Date of final enrolment

31/03/2018

Locations

Countries of recruitment

Japan

Study participating centre

Yokohama City University Hospital

Fuku-ura 3-9

Kanazawa-ku

Yokohama

Japan

236-0004

Sponsor information

Organisation

Yokohama City University

Funder(s)

Funder type

Other

Funder Name

The Japan Society for the Promotion of Science

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

IPD sharing plan summary

Available on request

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|-------------------------------|--------------|------------|----------------|-----------------|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |